MEMORANDUM FOR DEFENSE MEDICAL LOGISTICS PROPONENT COMMITTEE

SUBJECT: Pandemic Influenza Materiel Policy Guidance

This memorandum summarizes policy guidance about materiel stockpiled for pandemic influenza preparedness and response. Policy guidance for these stockpiles exists in multiple documents. This memorandum provides a brief compendium of those policy documents; it does not replace any policy.

The Department of Defense (DoD) medical materiel preparedness strategy includes stockpiles to store response materiel and corporate exigency contracts to guarantee access to materiel when required. The DoD stores pandemic vaccines, antiviral medication, antibiotics, and personal protective equipment (PPE). The Defense Logistics Agency-Troop Support provides corporate exigency contracts for access to ventilators and storage of needles and syringes.

Vaccines: The “Department of Defense Implementation Plan for Pandemic Influenza,” dated August 2006, directs the DoD to stockpile vaccine adequate to immunize 1.35 million active duty Service members against H5N1 Influenza and other influenza subtypes determined to represent a pandemic threat. The Department of Health and Human Services contracts for these vaccines, which are stored and tested by the manufacturer.

Antiviral Medications: In response to the “Department of Defense Implementation Plan for Pandemic Influenza” dated August 2006, the DoD positioned 2.4 million treatment courses of antiviral medications at worldwide locations.

a. Strategic stockpiles: The DoD positioned the stockpiles of Tamiflu™ and Relenza™ in the Pacific Rim, Europe, and the continental United States. These stockpiles are under the release authority of the Assistant Secretary of Defense for Health Affairs. In addition, the DoD established local and intermediate level stockpiles of Tamiflu™ and Relenza™ under the release and use authority of commanders of the individual Services and Geographic Combatant Commands. These stockpiles are for use during World Health Organization pandemic phases four through six, in support of the Combatant Command, Service, or agency Pandemic Influenza Plans.
b. Local stockpiles: The August 2007 policy memo entitled, “Policy for Release of DoD Antiviral Stockpile during an Influenza Pandemic,” authorizes select medical treatment facilities (MTFs) to maintain an additional supply of Tamiflu™ equal to 10% of their population at risk. In April 2008, guidance entitled, “Addendum to Policy for Release of DoD Antiviral Stockpile during an Influenza Pandemic,” authorized an increase in local supply levels of Tamiflu™ to 30% of population at risk at MTFs located in U.S. European Command and U.S. Pacific Command. The levels in MTFs in the continental United States remained at 10% due to storage restrictions. Lastly, a January 2010 memo entitled, “Addendum to Policy for Release of DoD Antiviral Stockpile during an Influenza Pandemic,” authorized the stockpile of Relenza™ to treat 15% of the population at risk.


**Antibiotics:** In 2006, we estimated that 10% of patients seeking treatment at MTFs would require antibiotics. The September 2006 memo entitled, “Centrally Funded Influenza Pandemic Response Materiel Guidance,” identified 10 antibiotics and gave the MTF commanders operational control of the antibiotics stored at their sites. The four intermediate storage site commanders (USAMMCE, USAMMC-Korea, USAMMC-South West Asia, and Port of San Antonio Base) control antibiotics held at their sites, but the combatant commander that each site supports maintains release authority. Stockpile managers may not reduce the stock levels, must take appropriate action to replace items when unserviceable, and must enter eligible product in the Shelf Life Extension Program to reduce replacement costs. Recently, Service Infectious Disease consultants identified substitute items to fill shortages when the preferred antibiotic is not available. The attached list identifies the current antibiotics along with approved substitutes.

**Personal Protection Equipment (PPE):** The September 2006 memo entitled, “Centrally Funded Influenza Pandemic Response Materiel Guidance,” authorized the Military Services to purchase and store five personal protection items (N95 respirations, surgical masks, gowns, exam gloves, and protective eye wear) to protect personnel who may have direct patient contact in the event of a pandemic. MTF Commanders have operational control of the PPE stored at their facilities. The January 2010 memo entitled, “H1N1 Supplemental Funds to Purchase Additional Personal Protective Equipment,” authorized the purchase of additional PPE with the first priority to increase the number of N95 respirators to eight per healthcare worker per day per MTF. After satisfying that requirement, the remaining funds would purchase additional
gloves, gowns, and masks. The materiel is for response to a pandemic or other public health emergency, so the materiel managers at each MTF must rotate the materiel as part of normal operations and replace stocks that become unserviceable or drop below safety levels.

My point of contact is COL Randy Story at 703-681-8284 or Randy.Story.mil@mail.mil.

Terry M. Rauch, Ph.D.
Acting Deputy Assistant Secretary of Defense
Health Readiness Policy and Oversight

Attachment:
Antibiotics For Influenza Pandemic Response
ANTIBIOTICS FOR INFLUENZA PANDEMIC RESPONSE

1. Cefepime, 2 grams IV, 20 ml, 10 Vials/Package
   6505-01-4376-6228, NDC 51479-0055-30, Treatment Course: 28 vials
   Substitute for Cefepime: Piperacillin/Tazobactam, 4.5 gm, vial, 10 vials per package,
   6505-01-541-2276, Treatment Course: 56 vials

2. Ceftriaxone Injection USP 1GM, SDV 6505-01-219-2760 NDC 00004-1964-01, Treatment
   Course: 28 vials

3. Imipenem and Cilastin Injection, 500 mg Imipenem and 500 mg Cilastin, 25s
   6505-01-332-4794, NDC 000060-3516-59, Treatment Course: 40 vials
   Substitute for Imipenem and Cilastin: Meropenem Inj, 1 gm/vial, 10 vials per package,
   6505-01-437-8683, NDC 00310-0321-30, Treatment Course: 30 vials

4. Vancomycin Hydrochloride Sterile USP 1GM Vial 10 Vials/Package
   6505-01-247-8801, NDC 00409-6533-01, Treatment course: 28 vials

5. Doxycycline Hyclate Tablets USP 100MG 500 Tablets per Bottle
   6505-01-153-4335, NDC 00172-3626-70, Treatment Course: 28 Tablets

6. Doxycycline Hyclate for Injection USP 100MG 10 Vials per Package
   6505-01-516-7604, NDC 63323-0130-11, Treatment Course: 28 vials

7. Levofoxacin 25MG/ML, 30 ML SDV
   6505-01-542-7929, NDC 00045-0065-55 or 17478-0107-30, Treatment Course: 5 vials

8. Levofoxacin Tablets 750 mg 100s,
   6505-01-487-6727, NDC 00045-1530-10, Treatment Course: 5 Tablets; or
   6505-01-444-6632, NDC 50458-0925-50, 500 mg, 50’s, Treatment Course: 14 tablets
   Substitute for Levofoxacin: Moxifloxacin HCL, 400mg, 50 tablets per BT,
   6505-01-516-3194, NDC 00085-1733-02, Treatment Course:

9. Amoxicillin and Clavulanate Potassium Tablets USP 20 Tabs/BT
   6505-01-430-9740, NDC 00093-2275-34, Treatment Course: 28 Tablets

10. Amoxicillin and Clavulanate Potassium for Oral Suspension 400MG/5ML,
    6505-01-505-5928, NDC 00093-2279-73, Treatment Course: 14